Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 100.00% is 294% above its 5-year average of 25.36%, near the high end of its 5-year range (-529.05%–100.00%).
25.00% above its 12-month average of 80.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
100.00%
GROSS MARGIN AVG TTM
80.00%
GROSS MARGIN AVG 3Y
17.99%
GROSS MARGIN AVG 5Y
25.36%
GROSS MARGIN AVG 10Y
70.12%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+25.00%
CURRENT VS 3Y AVG
+455.84%
CURRENT VS 5Y AVG
+294.26%
CURRENT VS 10Y AVG
+42.61%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 853 covered companies
CURRENT VS SECTOR MEDIAN
+141.66%
vs the sector median at left
Spero Therapeutics, Inc.
Market Cap
$68.32M
Gross Margin
100.00%
TTM Avg
80.00%
3Y Avg
17.99%
5Y Avg
25.36%
Market Cap
$68.43M
Gross Margin
62.53%
TTM Avg
65.36%
3Y Avg
65.75%
5Y Avg
64.06%
Market Cap
$68.08M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$69.75M
Gross Margin
49.30%
TTM Avg
49.08%
3Y Avg
46.18%
5Y Avg
47.39%
Market Cap
$72.34M
Gross Margin
60.78%
TTM Avg
57.02%
3Y Avg
54.79%
5Y Avg
56.72%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | $68.32M | 100.00% | 80.00% | 17.99% | 25.36% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.43M | 62.53% | 65.36% | 65.75% | 64.06% |
| Tiziana Life Sciences Ltd (TLSA)vs › | $68.08M | 0.00% | 0.00% | 0.00% | 0.00% |
| iBio, Inc. (IBIO)vs › | $67.52M | 100.00% | 100.00% | 75.00% | 39.52% |
| Champions Oncology, Inc. (CSBR)vs › | $69.75M | 49.30% | 49.08% | 46.18% | 47.39% |
| XBiotech Inc. (XBIT)vs › | $66.31M | 0.00% | 0.00% | 20.94% | 28.94% |
| Cingulate Inc. (CING)vs › | $66.20M | 0.00% | 0.00% | 0.00% | 0.00% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.34M | 60.78% | 57.02% | 54.79% | 56.72% |
| RenovoRx, Inc. (RNXT)vs › | $62.62M | 70.88% | 85.44% | 42.72% | 28.48% |
| Gossamer Bio, Inc. (GOSS)vs › | $64.80M | 99.56% | 98.97% | 49.48% | 32.99% |
Gross Margin
100.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 100.00% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | -131.63% |
| 2024-12-31 | -529.05% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | -132.67% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 32.76% |
| 2023-09-30 | 97.57% |
| 2023-06-30 | -250.15% |
| 2023-03-31 | -333.98% |
| 2022-12-31 | 100.00% |
| 2022-09-30 | 100.00% |
| 2022-06-30 | 100.00% |
| 2022-03-31 | 100.00% |
| 2021-12-31 | -527.73% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | -152.11% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | -343.20% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | -1101.41% |
| 2019-12-31 | -608.76% |
| 2019-09-30 | 100.00% |
| 2019-06-30 | 100.00% |
| 2019-03-31 | 100.00% |
| 2018-12-31 | 100.00% |
| 2018-09-30 | 100.00% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
| 2017-12-31 | 100.00% |
| 2017-09-30 | 100.00% |
| 2017-06-30 | 100.00% |
| 2017-03-31 | 100.00% |
| 2016-12-31 | 100.00% |
| 2016-09-30 | 0.00% |
